Aveo Pharmaceuticals, Inc.

Lorena Lerner

Jeno Gyuris

Ting Chen

William M Winston, Jr

Solly Weiler

Qing Liu

Maria Isabel Chiu

Ailin Bai

Zhigang Weng

Laura L Poling

Sandra Abbott

Nianjun Tao

Lyne Breault

Kristan Meetze

May Han

Sylvie Vincent

Steve Bottega

Kerry Whalen

Jinwei Jiang

James Gifford

Andrea Boudrow

Jie Lin

Murray Robinson

Ronan O'Hagan

Yinghui Zhou

Karuppiah Kannan

Ti Cai

William M Winston

Laura Poling

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Anti-GDF-15 antibodies

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (CKD), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits GDF15 activity.

Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator

Anti-GDF15 antibodies

Methods of treatment using anti-GDF15 antibodies

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d'Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-ron antibodies

Monoclonal antibodies that bind and inhibit activation of human RON (Recepteur d' Origine Nantais) are disclosed. The antibodies can be used to treat certain forms of cancer that are associated with activation of RON.

Anti-RON antibodies

A method of producing a tumorigenic mouse cell, the tumorigenicity of which depends on a recombinant gene of interest is disclosed. The method involves: (a) providing a conditionally tumorigenic mouse cell containing a recombinant oncogene operably linked to an inducible promoter, wherein (i) expression of the recombinant oncogene is necessary and sufficient for the tumorigenicity of the tumorigenic mouse cell, and (ii) the inducible promoter is in the uninduced state; and (b) introducing into the cell a recombinant gene of interest that functionally complements the oncogene, thereby restoring tumorigenicity without expression of the inducible recombinant oncogene. Also disclosed is a method of testing a compound for anti-tumor effects. The method includes producing tumorigenic mouse cells the tumorigenicity depends on expression of a recombinant gene of interest, implanting the cells in mice and obtaining tumors from the implanted cells, administering test compounds to the mice, and determining anti-tumor effects, if any, of the compounds.

Directed complementation

Growing community of inventors

Newton Centre, MA, United States of America

Lorena Lerner